Rezultaty - David R.P. Almeida
- Rezultaty 1 - 4 Rezultaty od 4
-
1
-
2
Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy od Eric K. Chin, David R.P. Almeida, C. Nathaniel Roybal, Philip Niles, Karen M. Gehrs, Elliott H. Sohn, H. Culver Boldt, Stephen R. Russell, James C. Folk
Wydane 2015Artigo -
3
OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT od Eric K. Chin, David R.P. Almeida, Gabriel Velez, Kunyong Xu, María Peraire, Maria Corbella, Yasser Elshatory, Young H. Kwon, Karen M. Gehrs, H. Culver Boldt, Elliott H. Sohn, Stephen R. Russell, James C. Folk, Vinit B. Mahajan
Wydane 2016Artigo -
4
The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results od Arshad M. Khanani, Aamir Aziz, Hannah Khan, Ashwin Gupta, Ohidul Mojumder, Aigerim Saulebayeva, Ashkan M. Abbey, David R.P. Almeida, Robert L. Avery, Himanshu Banda, Mark Barakat, Ramanath Bhandari, Emmanuel Chang, Sara J. Haug, Nikolas London, Luke Mein, Veeral Sheth, Jeremy D. Wolfe, Michael Singer, Carl J. Danzig
Wydane 2023Artigo
Narzędzie wyszukiwania:
Podobne hasła
Internal medicine
Medicine
Ophthalmology
Surgery
Visual acuity
Adverse effect
Aldosterone
Confidence interval
Demographics
Demography
Dexamethasone
Endophthalmitis
Eplerenone
Eye examination
Glaucoma
Glaucoma surgery
Implant
Intraocular pressure
Macular degeneration
Mineralocorticoid
Mineralocorticoid receptor
Ocular hypertension
Physical examination
Posterior vitreous detachment
Retinal
Retinal detachment
Retrospective cohort study
Serous fluid
Sociology
Spironolactone